Key facts
- MitoRx Therapeutics’s last known valuation is $31.4M (Nov 2025).
- It has raised $17.5M; the latest was Early Stage VC ($9.6M) in Nov 2025.
- Notable investors include Future Planet Capital, UK Innovation & Science Seed Fund, WCS Nominees, Empirical Ventures, The Betsy and Jesse Fink Family Foundation — 13 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 13 names
- ·Watchlist + deal alerts for MitoRx Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for MitoRx Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About MitoRx Therapeutics
Developer of small molecule therapeutics designed for weight loss with muscle preservation in obesity-related and cardiometabolic conditions. The company is advancing mitochondrial-targeted persulfide modifiers that restore a signaling mechanism identified through population-based studies, with preclinical data demonstrating efficacy against hepatosteatosis, effectiveness as a monotherapy, and enhanced fat loss with lean mass gain when combined with glucagon-like peptide-1 receptor agonists, enabling biopharmaceutical developers and healthcare providers to access a foundational therapeutic modality that tackles underlying cellular dysfunction to potentially improve patient outcomes across a spectrum of metabolic and degenerative disorders.
- Sector
- Healthcare
- HQ
- Oxford, United Kingdom
- Founded
- 2021
- Employees
- 14
- Website
- mitorxtherapeutics.com/
- Ownership
- Privately Held (backing)
MitoRx Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in MitoRx Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on MitoRx Therapeutics in its N-PORT filings yet. We sweep new filings monthly.